• SHAPERON
    First-in class anti-inflammatory NME targeting TGR5
    For atopic dermatitis, ulcerative colitis,
    sepsis and Alzheimer’s disease
  • SHAPERON
    API Increases number of immune regulatory cells resolving inflammation
    such as myeloid-derived
    suppressor cells or regulatory T cells
  • SHAPERON
    Novel platform for nanobody-drug conjugates
    for enhanced tissue distribution and
    lower side effects of conventional ADC